Unicycive Therapeutics, Inc. (17) | Intellectual Property (2)
- License Agreement effective as of July 14, 2022 by and between Unicycive Therapeutics, Inc. and Lees Pharmaceutical (HK) Limited (Filed With SEC on July 18, 2022)
- Exclusive License Agreement by and between the Company and Sphaera Pharma Pte. Ltd., dated October 1, 2017 (Filed With SEC on June 7, 2021)